Terazosin labels and packages: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
{| | {| | ||
| [[image:tera11. | | [[image:tera11.jpg|400px|thumb]] | ||
|} | |} | ||
| Line 24: | Line 24: | ||
{| | {| | ||
| [[image:tera12. | | [[image:tera12.jpg|400px|thumb]] | ||
|} | |} | ||
Revision as of 19:39, 12 March 2014
| Terazosin |
|---|
| Terazosin®, Hytrin® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Terazosin |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
PRINCIPAL DISPLAY PANEL TERAZOSIN HYDROCHLORIDE CAPSULES 1 MG
Terazosin Hydrochloride
Capsules 1 mg.*
10 Capsules
 |
PRINCIPAL DISPLAY PANEL TERAZOSIN HYDROCHLORIDE CAPSULES 5 MG
Terazosin Hydrochloride
Capsules 5 mg.*
10 Capsules
 |
References
- ↑ "TERAZOSIN HYDROCHLORIDE CAPSULE [CARDINAL HEALTH]". Retrieved 7 March 2014.